GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018
SEOM clinical guideline on unknown primary cancer (2017).
Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.The oncologist · 2021Trial
- HPV16-Positive Pelvic Nodal Squamous Cell Carcinoma with No Detectable Cervical Malignancy.Diagnostics (Basel, Switzerland) · 2026Article
- Aggressive Squamous Cell Carcinoma of Unknown Primary: Isolated Inguinal Metastasis and Uncommon Progression.The American journal of case reports · 2025Article
- PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.International journal of clinical oncology · 2024Article
- Article
- Exceptional response to immunotherapy monotherapy in a patient with an unfavorable subset of cancer of unknown primary.Quantitative imaging in medicine and surgery · 2023Article
- Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.Journal of gastrointestinal cancer · 2023Article
- Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.ESMO open · 2023Article
- Cancer of unknown primary site in the mandibular region: A case report.Oncology letters · 2023Article
- From Biology to Diagnosis and Treatment: The Ariadne's Thread in Cancer of Unknown Primary.International journal of molecular sciences · 2023Review
- Review
- Nationwide survey on family caregiver-perceived experiences of patients with cancer of unknown primary site.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Gastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation.Cureus · 2022Article
- Article
- Late presentation during the COVID-19 pandemic of severe procidentia: a high-grade poorly differentiated sarcoma of unknown origin.BMJ case reports · 2022Article
- Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary.Frontiers in immunology · 2022Article
- Article
- Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX.Journal of medical cases · 2021Article
- Leveraging Genetic Reports and Electronic Health Records for the Prediction of Primary Cancers: Algorithm Development and Validation Study.JMIR medical informatics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of unknown primary site is a histologically confirmed cancer that manifests in advanced stage, with no identifiable primary site following standard diagnostic procedures. Patients are initially categorized based on the findings of the initial biopsy: adenocarcinoma, squamous-cell carcinoma, neuroendocrine carcinoma, and poorly differentiated carcinoma. Appropriate patient management requires understanding several clinical and pathological features that aid in identifying several subsets of patients with more responsive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.